|
Name |
3alpha-Hydroxytauranin
|
| Molecular Formula | C22H30O5 | |
| IUPAC Name* |
2-[[(1S,4aR,6R,8aR)-6-hydroxy-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]methyl]-3-hydroxy-5-(hydroxymethyl)cyclohexa-2,5-diene-1,4-dione
|
|
| SMILES |
C[C@]12CC[C@H](C([C@@H]1CCC(=C)[C@@H]2CC3=C(C(=O)C(=CC3=O)CO)O)(C)C)O
|
|
| InChI |
InChI=1S/C22H30O5/c1-12-5-6-17-21(2,3)18(25)7-8-22(17,4)15(12)10-14-16(24)9-13(11-23)19(26)20(14)27/h9,15,17-18,23,25,27H,1,5-8,10-11H2,2-4H3/t15-,17-,18+,22+/m0/s1
|
|
| InChIKey |
BJEQCQQYHRYXQG-CTWQGKMFSA-N
|
|
| Synonyms |
3alpha-Hydroxytauranin; 1012335-00-0
|
|
| CAS | NA | |
| PubChem CID | 24800191 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 374.5 | ALogp: | 2.9 |
| HBD: | 3 | HBA: | 5 |
| Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 94.8 | Aromatic Rings: | 3 |
| Heavy Atoms: | 27 | QED Weighted: | 0.516 |
| Caco-2 Permeability: | -5.434 | MDCK Permeability: | 0.00000513 |
| Pgp-inhibitor: | 0.142 | Pgp-substrate: | 0.723 |
| Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.96 |
| 30% Bioavailability (F30%): | 0.534 |
| Blood-Brain-Barrier Penetration (BBB): | 0.038 | Plasma Protein Binding (PPB): | 97.51% |
| Volume Distribution (VD): | 1.839 | Fu: | 2.50% |
| CYP1A2-inhibitor: | 0.075 | CYP1A2-substrate: | 0.347 |
| CYP2C19-inhibitor: | 0.054 | CYP2C19-substrate: | 0.303 |
| CYP2C9-inhibitor: | 0.374 | CYP2C9-substrate: | 0.82 |
| CYP2D6-inhibitor: | 0.112 | CYP2D6-substrate: | 0.254 |
| CYP3A4-inhibitor: | 0.125 | CYP3A4-substrate: | 0.192 |
| Clearance (CL): | 10.207 | Half-life (T1/2): | 0.691 |
| hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.071 |
| Drug-inuced Liver Injury (DILI): | 0.025 | AMES Toxicity: | 0.237 |
| Rat Oral Acute Toxicity: | 0.182 | Maximum Recommended Daily Dose: | 0.931 |
| Skin Sensitization: | 0.855 | Carcinogencity: | 0.024 |
| Eye Corrosion: | 0.009 | Eye Irritation: | 0.894 |
| Respiratory Toxicity: | 0.958 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003214 | ![]() |
0.753 | D04VIS | ![]() |
0.429 | ||
| ENC002490 | ![]() |
0.735 | D0S0NK | ![]() |
0.317 | ||
| ENC002494 | ![]() |
0.706 | D0D2VS | ![]() |
0.279 | ||
| ENC002172 | ![]() |
0.453 | D0R7JT | ![]() |
0.272 | ||
| ENC001621 | ![]() |
0.429 | D06XMU | ![]() |
0.272 | ||
| ENC002492 | ![]() |
0.396 | D0L2LS | ![]() |
0.269 | ||
| ENC000956 | ![]() |
0.369 | D0IX6I | ![]() |
0.265 | ||
| ENC002941 | ![]() |
0.368 | D0D1SG | ![]() |
0.265 | ||
| ENC002748 | ![]() |
0.367 | D0KR5B | ![]() |
0.265 | ||
| ENC005461 | ![]() |
0.360 | D0IL7L | ![]() |
0.265 | ||